Brand Name

Methazolamide

View Brand Information
FDA approval date: June 30, 1993
Form: Tablet

What is Methazolamide?

Methazolamide Tablets, USP are indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Efficient quantification of methazolamide in rat plasma using UHPLC-Q-Orbitrap MS for pharmacokinetic analysis.
Efficient quantification of methazolamide in rat plasma using UHPLC-Q-Orbitrap MS for pharmacokinetic analysis.
Journal: Analytical methods : advancing methods and applications
Published: January 26, 2026
Antioxidants Trolox and Methazolamide Protect Microvascular Endothelial Cells from Oxidative Damage Induced by Sporadic and Familial Forms of Oligomeric Amyloid-β.
Antioxidants Trolox and Methazolamide Protect Microvascular Endothelial Cells from Oxidative Damage Induced by Sporadic and Familial Forms of Oligomeric Amyloid-β.
Journal: Antioxidants (Basel, Switzerland)
Published: August 05, 2025
High-altitude retinopathy with isolated ellipsoid zone loss: a case report.
High-altitude retinopathy with isolated ellipsoid zone loss: a case report.
Journal: Documenta ophthalmologica. Advances in ophthalmology
Published: July 19, 2025
View All Latest Advances